The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians. Ann Oncol 2020 Sep;31(9):1115-1118
Date
08/11/2020Pubmed ID
32771306DOI
10.1016/j.annonc.2020.07.002Scopus ID
2-s2.0-85089498915 (requires institutional sign-in at Scopus site) 139 CitationsAuthor List
Subbiah V, Solit DB, Chan TA, Kurzrock RAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAntibodies, Monoclonal, Humanized
Child
Humans
Neoplasms
Physicians